SNHG10 has been confirmed as a malignant gene in hepatocellular carcinoma (Lan et al., 2019; Zhu et al., 2019), gastric cancer (Zhang Y et al., 2021; Yuan et al., 2021), glioma (Jin et al., 2020), osteosarcoma (He et al., 2020; Zhu et al., 2020), and acute myeloid leukemia (Xiao et al., 2021), while it was certified as a suppressor in non-small cell lung cancer (Zhang et al., 2020b) and our study. The gene discussed is SNHG10; the disease is central nervous system cancer.